AARVAP HEALTH INC

SPONSOR CAPABILITY PRESENTATION

Clinical research, managed with clarity.

Flexible clinical research support for biotech and pharmaceutical sponsors.

FOCUSED

Senior attention

FLEXIBLE

Right-sized delivery

VISIBLE

Governance that drives decisions

A sharper line of sight from plan to execution.

Aarvap combines senior operational attention with an engagement model that can expand as the program evolves.

Senior attention	Leadership stays close to execution and sponsor decisions.
Fit-for-purpose teams	Roles, cadence, and controls align to study complexity.
Transparent delivery	Progress, dependencies, and forecast changes remain visible.

A right-sized CRO model keeps decisions close to delivery

Sponsor priorities stay connected to daily execution, emerging risks, and the forecast.

SPONSOR PRIORITY	CONNECTED EXECUTION
Sponsor objectives	**Daily study execution**
Emerging risks	**Visible ownership and impact**
Milestones and forecast	**Timely, documented decisions**
Evolving program needs	**Flexible resourcing and scope**

ONE PARTNER ACROSS THE CLINICAL LIFECYCLE

Engage an integrated team—or select the functions your program needs most.

PLAN	**Strategy & feasibility**	Protocol review • country/site strategy • feasibility • enrollment planning
ACTIVATE	**Study start-up**	Regulatory coordination • essential documents • activation • readiness tracking
EXECUTE	**Clinical operations**	Project leadership • monitoring • site management • vendor coordination
CONTROL	**Data, safety & quality**	Data coordination • safety oversight • TMF controls • risk management
CLOSE	**Closeout & readiness**	Reconciliation • site closeout • inspection readiness

SELECT THE CAPABILITIES THAT CLOSE YOUR EXECUTION GAPS

Scope can begin with one high-priority function and grow with the asset.

Study strategy

Protocol and operational review
Feasibility planning
Country and site strategy

Site activation

Regulatory coordination
Essential-document collection
Site activation tracking

Study delivery

Project leadership
CRA monitoring and oversight
Site and vendor management

Quality readiness

Risk and issue controls
TMF oversight
Closeout and inspection support

Designed to integrate with sponsor systems, vendors, and governance—not duplicate them.

THREE WAYS TO ENGAGE

The delivery model can flex with funding, stage, and internal capacity

FULL-SERVICE	**Integrated ownership across agreed study functions**	Best for a defined study or research program
FUNCTIONAL SERVICE	**Focused capability embedded within sponsor governance**	Best for monitoring, start-up, PM, feasibility, or another function
HYBRID / ADAPTIVE	**Shared ownership that evolves with program needs**	Best for programs requiring flexibility across stages

Clinical leadership stays close to the work

Our team brings hands-on experience across Phase I–IV trials, multiple therapeutic areas, and the full study lifecycle.

PHASE I–IV TEAM

Across all trial phases

Feasibility and start-up
Clinical operations and monitoring
Quality oversight
Closeout readiness

FULL LIFECYCLE	Feasibility and start-up through monitoring, quality, and closeout
QUALIFIED RESOURCING	Roles, qualifications, availability, and responsibilities aligned to scope
VISIBLE GOVERNANCE	Decisions, owners, due dates, and operational impact remain clear
THERAPEUTIC CONTEXT	Experience across seven therapeutic areas and Phase I–IV trials

Prepared for operational complexity

Our team’s experience includes seven therapeutic areas across Phase I–IV clinical trials.

ONCOLOGY	Complex protocols • safety oversight • specialized sites • cross-functional delivery
OPHTHALMOLOGY	Specialized assessments • imaging workflows • endpoints • site readiness
CNS	Longitudinal follow-up • site engagement • operational risk management
DIABETES & CARDIOVASCULAR	Patient-focused delivery • site oversight • data and safety coordination
DERMATOLOGY & VACCINES	Site readiness • monitoring • enrollment support across diverse populations

Sponsor confidence begins with scope-specific planning, qualified resourcing, transparent governance, and quality-focused oversight.

LEADERSHIP

Clinical operations
Start-up and monitoring
Feasibility and team leadership

PROPOSED TEAM

Named roles and qualifications
Availability and responsibilities
Escalation coverage

DELIVERY PLAN

Scope-specific timelines
Assumptions and dependencies
Governance and risk controls

QUALITY FOUNDATION

SOPs and training
Vendor qualification
TMF and oversight approach

Scope, team, delivery plan, and quality approach are confirmed before mobilization.

A clear governance rhythm keeps risk and decisions visible

Study information becomes actionable through defined ownership, escalation, and follow-through.

1

ALIGN

Confirm scope, milestones, roles, and decision rights

2

TRACK

Maintain integrated status, risks, dependencies, and forecasts

3

DECIDE

Escalate with context, options, owners, and due dates

4

ADAPT

Adjust resources and controls as program needs change

Quality is built into how the study is run

Critical-to-quality factors become operational controls, review points, and documented decisions—not final-stage cleanup.

DEFINE CRITICAL DATA	Identify critical data, processes, participant protections, and operational dependencies.
SET OWNERS & THRESHOLDS	Establish owners, review thresholds, escalation paths, and oversight cadence.
REVIEW DELIVERY SIGNALS	Review site, data, quality, and delivery signals to identify emerging risk.
DOCUMENT EFFECTIVENESS	Document decisions, actions, follow-through, and evidence of effectiveness.

Strong site partnerships support stronger study delivery

Aarvap welcomes investigators and research sites interested in future clinical trial opportunities.

WHAT WE LOOK FOR

Qualified investigators
Appropriate patient access
Experienced research staff
Reliable enrollment planning
Quality-focused execution

HOW TO CONNECT

Share therapeutic expertise
Describe site capabilities
Outline patient populations
Summarize relevant experience
investigators@aarvap.com

Four practical entry points let sponsors address an immediate need before expanding the relationship.

FEASIBILITY PACKAGE

Protocol review, country/site strategy, feasibility outreach and recommendation

START-UP SUPPORT

Essential documents, regulatory coordination, site activation tracking and escalation

MONITORING & SITE MANAGEMENT

CRA monitoring, site engagement, issue follow-through and report oversight

PROJECT MANAGEMENT

Integrated timelines, cross-functional coordination, risk management and sponsor reporting

Start with a scoped engagement and prove the model

The first assignment should have clear outputs, decision rights, measures, and a practical path to expand.

01	02	03	04	05
DISCOVER	**DESIGN**	**MOBILIZE**	**DELIVER**	**REVIEW**
Program stage, priorities, constraints	Scope, roles, timeline, governance	Team, systems, training, controls	Execution, reporting, escalation	Evidence, lessons, next scope

Define the right first engagement: program stage • countries • sites • milestones • scope • governance • evidence expectations

AARVAP HEALTH INC

DEFINE THE RIGHT FIRST ENGAGEMENT.

SPONSORS & PARTNERS

info@aarvap.com

INVESTIGATORS & RESEARCH SITES
investigators@aarvap.com

AARVAP HEALTH INC.

CLINICAL RESEARCH ORGANIZATION

Align program stage, scope, ownership, and evidence needs.

Clinical research, managed with clarity.